학술논문
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
Document Type
Article
Author
Source
In: Nature Communications . (Nature Communications, December 2023, 14(1))
Subject
Language
English
ISSN
20411723